RUA Life Sciences PLC
Company Profile
Business description
RUA Life Sciences PLC is engaged in contract design and manufacture of medical devices and exploiting the value of its IP and know-how, and developing of cardiovascular devices. Its segments include Biomaterials includes Licensor of Elast-Eon polymers to the medical device industry; Medical Devices and Components engages End-to-end contract developer, manufacturer, and seller of medical devices and implantable fabric specialist; Vascular engages in the development and commercialization of the group’s Elast-Eon sealed Vascular Graft products; and Structural Heart engages in the development of the group’s Elast-Eon composite heart valve material AurTex. Geographically it operates in Europe, North America, Middle East , Asia Pacific, and Africa.
Contact
2 Drummond Crescent
Ayrshire
Scotland
IrvineKA11 5AN
GBRT: +44 1294317073
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 March 2026
Employees
40
Stocks News & Analysis
stocks
Best sustainable companies to own in 2026
stocks
New data centre deal for ASX listed REIT
stocks
The best way to get rich and retire early
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,036.60 | 29.50 | 0.33% |
| CAC 40 | 8,195.21 | 45.71 | 0.56% |
| DAX 40 | 24,539.34 | 48.93 | 0.20% |
| Dow JONES (US) | 48,382.39 | 319.10 | 0.66% |
| FTSE 100 | 9,951.14 | 19.76 | 0.20% |
| HKSE | 26,338.47 | 707.93 | 2.76% |
| NASDAQ | 23,235.63 | 6.36 | -0.03% |
| Nikkei 225 | 50,339.48 | 187.44 | -0.37% |
| NZX 50 Index | 13,548.42 | 0.29 | 0.00% |
| S&P 500 | 6,858.47 | 12.97 | 0.19% |
| S&P/ASX 200 | 8,727.80 | 27.10 | 0.31% |
| SSE Composite Index | 3,968.84 | 3.72 | 0.09% |